MedTrace Logo

Anisakis Blastocystis Cryptosporidium Fish Prevalence

NCT02661074 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 486

Last updated 2026-05-14

No results posted yet for this study

Summary

Anisakidae frequently infect fish species that are commonly eaten by humans. Some of them are recognized as zoonotic agents, and have a high impact on human health.

Infestation results from the ingestion of living larvae from contaminated fishes. It can be asymptomatic or symptomatic, resulting in acute gastric, acute intestinal or chronic forms. Allergic manifestations are frequently encountered in gastric forms, but isolated allergic symptoms can occur after ingestion of Anisakidae antigens in raw or cooked fish. Cutaneous contact or Anisakis allergen inhalation have also been reported to induce allergy/anaphylactic reactions or sensitization in the occupational setting in Spain, Italy, Sicilia or South Africa. But no data is available in France.

In this context, the investigators propose to determine and compare the frequency and characteristics of fish allergy in fish workers (fishermen and fish-processing factory workers) and a control population of workers without occupational exposure to fish, in Boulogne-sur-Mer, which is an important fishing port in France, and the first European center for fish processing.

Conditions

  • Anisakis
  • Allergy
  • Occupational Exposure

Interventions

OTHER

Questionnaire

A questionnaire will be completed in order to collect data on: * Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis), * Occupational and/or domestic exposure to fish.

Sponsors & Collaborators

  • Institut Pasteur de Lille

    collaborator OTHER

  • ANSES

    collaborator OTHER

  • Région Nord-Pas de Calais, France

    collaborator OTHER

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Emmanuel DUTOIT, MD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02661074 on ClinicalTrials.gov